GATA 结合蛋白 3 (GATA3) 对于乳腺的正常发育至关重要，并与 ER 阳性乳腺癌相关。在实验研究中，GATA3 的缺失与上皮间质转化 (EMT) 相关。我们研究了一组绝经后淋巴结阴性乳腺癌患者的肿瘤 GATA3，随机接受他莫昔芬辅助治疗或对照。通过免疫组织化学评估细胞核 GATA3 表达，并通过安捷伦微阵列评估 GATA3 基因表达。高 GATA3 核表达与 ER 阳性乳腺癌较低的远处复发率相关（HR = 0.60，95% CI 0.39-0.93）。 GATA3 基因表达低与辅助他莫昔芬的长期获益有限相关（交互作用：p = 0.033）。 GATA3 基因表达与上皮标记物 CDH1（E-钙粘蛋白）和 FOXA1 相关，而与几种间充质标记物呈负相关。 CDH1的低表达与边际他莫昔芬获益相关（HR = 0.80（0.43-1.49）），而高表达的患者则表现出显着的获益（HR = 0.33（0.20-0.55），交互作用：p = 0.029）。在 ER 阳性乳腺癌中，GATA3 表达减少与 EMT 标志物以及他莫昔芬的长期获益不佳相关。© 2024。作者。

GATA binding protein 3 (GATA3) is essential for normal development of the mammary gland and associated with ER-positive breast cancer. Loss of GATA3 has been associated with epithelial-mesenchymal transition (EMT) in experimental studies. We investigated tumoral GATA3 in a cohort of postmenopausal patients with lymph-node negative breast cancer, randomized to adjuvant tamoxifen or control. Nuclear GATA3 expression was assessed with immunohistochemistry and GATA3 gene expression with Agilent microarrays. High GATA3 nuclear expression was associated with a lower rate of distant recurrence in ER-positive breast cancer (HR = 0.60, 95% CI 0.39-0.93). Low gene expression of GATA3 was associated with limited long-term benefit from adjuvant tamoxifen (interaction: p = 0.033). GATA3 gene expression was associated with the epithelial markers CDH1 (E-cadherin) and FOXA1, whereas negatively associated with several mesenchymal markers. Low expression of CDH1 was associated with marginal tamoxifen benefit (HR = 0.80 (0.43-1.49)), whereas patients with higher expression showed a significant benefit (HR = 0.33 (0.20-0.55), interaction: p = 0.029). In ER-positive breast cancer, diminished expression of GATA3 is associated with markers of EMT and poor long-term benefit from tamoxifen.© 2024. The Author(s).